Phaseline

Companies › Orano Med

Orano Med: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
212Pb-DOTAMTATE (AlphaMedix)
Somatostatin receptor 2 (SSTR2)-targeting alpha-emitter therapy; radiolabeled octreotide a
SSTR2Phase 2Neuroendocrine TumorsDec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05153772212Pb-DOTAMTATE (AlphaMedix)Phase 2Neuroendocrine TumorsOncologyDec 2030

Targets

SSTR2 (1)

Companies with the same targets

Novartis Sinotau Pharmaceutical Group HTA RayzeBio ITM Solucin Nanjing Chia-tai Tianqing Pharmaceutical Camurus Jiangsu HengRui Medicine Advanced Accelerator Applications CSPC ZhongQi Pharmaceutical Technology

Companies built like this

ITM Solucin Advanced Accelerator Applications Newish Technology (Beijing) BrainChild Bio TVAX Biomedical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.